17-hydroxyprogesterone ester-containing oral compositions and related methods
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
1. A method of treating a pregnant female subject at risk of preterm birth, comprising, administering to the female subject an oral pharmaceutical composition comprising a therapeutically effective amount of 17-hydroxyprogesterone caproate and a pharmaceutically acceptable carrier comprising a lipophilic additive selected from benzyl benzoate, castor oil and mixtures thereof, said lipophilic additive comprising at least 50 weight/weight percent (w/w %) of the carrier and said pharmaceutical composition having 50 w/w % or less castor oil and 50 w/w % or less benzyl benzoate wherein said pharmaceutical composition when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% w/w sodium lauryl sulfate at 50 RPM at 37° C., releases at least 20% of the 17-hydroxyprogesterone caproate at 60 minutes with the proviso that composition does not include benzyl alcohol.
2. The method of claim 1 wherein said carrier comprises a polyethylene glycol sorbitan fatty acid ester, a polyethylene glycol alkyl ether, a sugar ester, a polyethylene glycol phenol, a polyoxyethylene-polyoxypropylene block copolymer, a sorbitan fatty acid ester, a lower alcohol fatty acid ester or an ionic surfactant.
3. The method of claim 1 wherein the composition is formulated for pregnancy support.
4. The method of claim 1 wherein the 17-hydroxyprogesterone caproate is present in the composition in particulate form having a mean particulate diameter of about 50 micron or less.
5. The method of claim 1 wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to about 80% w/w of the total composition.
6. The method of claim 1 wherein the pharmaceutical composition is in the form of a capsule or a tablet.
7. The method of claim 6 , wherein the composition is in the form of a capsule and the capsule includes from about 30 mg to about 300 mg of 17-hydroxyprogesterone caproate.
8. The method of claim 6 , wherein the composition is in the form of a tablet and the tablet includes from about 20 mg to about 800 mg of 17-hydroxyprogesterone caproate.
9. The method of claim 6 , wherein the capsule or tablet is a controlled release oral dosage form.
10. The method of claim 6 , wherein the ratio of the amount of 17-hydroxyprogesterone caproate in the composition to the fill volume of the capsule is from about 0.02 g/mL to about 0.8 g/mL.
11. The method of claim 1 wherein the carrier includes a hydrophilic additive.
12. The method of claim 1 wherein the carrier includes a lipophilic additive.
13. The method of claim 1 wherein the carrier includes at least one hydrophilic additive and at least one lipophilic additive at a lipophilic additive to hydrophilic additive ratio of about 90:10 to about 1:99.